Monthly Prescribing Reference11d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
Participants were randomly assigned to receive Trikafta or placebo based on age and weight: Aged 6 to <12 years and less than 30kg: morning dose of elexacaftor 100mg/tezacaftor 50mg/ivacaftor 75mg ...
Business Wire18d
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ® (elexacaftor ...
Nasdaq17d
Vertex announces FDA exands approval for Trikafta
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...
Bizcommunity26d
Cystic fibrosis drug access secured in South Africa
After its investigation, the Commission secured Vertex's commitment to keep Trikafta available in South Africa under Section 21, allowing unregistered drug sales. The Commission accepts Vertex's ...
STAT25d
South African regulator decides Vertex provides sufficient access to CF drugs, angering activists
generic versions of Trikafta, a particularly effective triple-combination treatment for the disease, which causes the body to produce thick, sticky mucus that damages the lungs and other organs.